IDEXX LABORATORIES INC (IDXX) Stock Fundamental Analysis
USA - NASDAQ:IDXX - US45168D1046 - Common Stock
689.93 USD
-11.55 (-1.65%)
689.93 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to IDXX. IDXX was compared to 189 industry peers in the Health Care Equipment & Supplies industry. IDXX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IDXX has a correct valuation and a medium growth rate. This makes IDXX very considerable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year IDXX was profitable.
In the past year IDXX had a positive cash flow from operations.
IDXX had positive earnings in each of the past 5 years.
Each year in the past 5 years IDXX had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 30.34%, IDXX belongs to the best of the industry, outperforming 99.47% of the companies in the same industry.
The Return On Equity of IDXX (65.81%) is better than 99.47% of its industry peers.
IDXX has a Return On Invested Capital of 40.25%. This is amongst the best in the industry. IDXX outperforms 99.47% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IDXX is significantly above the industry average of 8.99%.
The last Return On Invested Capital (40.25%) for IDXX is above the 3 year average (35.08%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.25% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
1.3 Margins
Looking at the Profit Margin, with a value of 24.65%, IDXX belongs to the top of the industry, outperforming 94.18% of the companies in the same industry.
IDXX's Profit Margin has improved in the last couple of years.
IDXX has a better Operating Margin (31.34%) than 98.41% of its industry peers.
IDXX's Operating Margin has improved in the last couple of years.
The Gross Margin of IDXX (61.72%) is better than 64.02% of its industry peers.
In the last couple of years the Gross Margin of IDXX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
2. Health
2.1 Basic Checks
IDXX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for IDXX has been reduced compared to 1 year ago.
Compared to 5 years ago, IDXX has less shares outstanding
IDXX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 23.26 indicates that IDXX is not in any danger for bankruptcy at the moment.
IDXX has a better Altman-Z score (23.26) than 96.83% of its industry peers.
The Debt to FCF ratio of IDXX is 1.04, which is an excellent value as it means it would take IDXX, only 1.04 years of fcf income to pay off all of its debts.
IDXX has a Debt to FCF ratio of 1.04. This is amongst the best in the industry. IDXX outperforms 91.01% of its industry peers.
IDXX has a Debt/Equity ratio of 0.53. This is a neutral value indicating IDXX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.53, IDXX is in line with its industry, outperforming 40.74% of the companies in the same industry.
Even though the debt/equity ratio score it not favorable for IDXX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 23.26 |
ROIC/WACC4.41
WACC9.12%
2.3 Liquidity
IDXX has a Current Ratio of 1.18. This is a normal value and indicates that IDXX is financially healthy and should not expect problems in meeting its short term obligations.
IDXX has a worse Current ratio (1.18) than 83.07% of its industry peers.
IDXX has a Quick Ratio of 1.18. This is a bad value and indicates that IDXX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.87, IDXX is doing worse than 83.60% of the companies in the same industry.
The current and quick ratio evaluation for IDXX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 15.16% over the past year.
IDXX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.18% yearly.
IDXX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.39%.
Measured over the past years, IDXX shows a quite strong growth in Revenue. The Revenue has been growing by 10.12% on average per year.
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
3.2 Future
Based on estimates for the next years, IDXX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.68% on average per year.
IDXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.69% yearly.
EPS Next Y14.37%
EPS Next 2Y13.33%
EPS Next 3Y13.16%
EPS Next 5Y11.68%
Revenue Next Year9.1%
Revenue Next 2Y8.66%
Revenue Next 3Y8.63%
Revenue Next 5Y8.69%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 54.71, which means the current valuation is very expensive for IDXX.
IDXX's Price/Earnings ratio is a bit cheaper when compared to the industry. IDXX is cheaper than 67.20% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.89. IDXX is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 47.75 indicates a quite expensive valuation of IDXX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 69.31% of the companies listed in the same industry.
IDXX is valuated rather expensively when we compare the Price/Forward Earnings ratio to 34.59, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.71 | ||
| Fwd PE | 47.75 |
4.2 Price Multiples
IDXX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. IDXX is cheaper than 68.78% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IDXX is valued a bit cheaper than 72.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 58.7 | ||
| EV/EBITDA | 38.38 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of IDXX may justify a higher PE ratio.
IDXX's earnings are expected to grow with 13.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.81
PEG (5Y)3.01
EPS Next 2Y13.33%
EPS Next 3Y13.16%
5. Dividend
5.1 Amount
IDXX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
689.93
-11.55 (-1.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners97.04%
Inst Owner Change0.61%
Ins Owners0.2%
Ins Owner Change1.93%
Market Cap55.19B
Revenue(TTM)4.17B
Net Income(TTM)1.03B
Analysts80
Price Target697.54 (1.1%)
Short Float %2.24%
Short Ratio4.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)0.44%
PT rev (3m)15.42%
EPS NQ rev (1m)0.87%
EPS NQ rev (3m)1.43%
EPS NY rev (1m)0.13%
EPS NY rev (3m)3.64%
Revenue NQ rev (1m)1.02%
Revenue NQ rev (3m)1.11%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)2.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.71 | ||
| Fwd PE | 47.75 | ||
| P/S | 13.24 | ||
| P/FCF | 58.7 | ||
| P/OCF | 50.73 | ||
| P/B | 35.35 | ||
| P/tB | 53.44 | ||
| EV/EBITDA | 38.38 |
EPS(TTM)12.61
EY1.83%
EPS(NY)14.45
Fwd EY2.09%
FCF(TTM)11.75
FCFY1.7%
OCF(TTM)13.6
OCFY1.97%
SpS52.09
BVpS19.51
TBVpS12.91
PEG (NY)3.81
PEG (5Y)3.01
Graham Number74.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.25% | ||
| ROICexc | 43.77% | ||
| ROICexgc | 56.25% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
ROICexc(3y)39.8%
ROICexc(5y)41.54%
ROICexgc(3y)51.52%
ROICexgc(5y)54.7%
ROCE(3y)52.73%
ROCE(5y)50.92%
ROICexgc growth 3Y-5.99%
ROICexgc growth 5Y4.28%
ROICexc growth 3Y-3.86%
ROICexc growth 5Y4.07%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 23.26 |
F-Score8
WACC9.12%
ROIC/WACC4.41
Cap/Depr(3y)119.67%
Cap/Depr(5y)117.13%
Cap/Sales(3y)3.91%
Cap/Sales(5y)3.89%
Profit Quality(3y)79.31%
Profit Quality(5y)83.23%
High Growth Momentum
Growth
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
EPS Next Y14.37%
EPS Next 2Y13.33%
EPS Next 3Y13.16%
EPS Next 5Y11.68%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
Revenue Next Year9.1%
Revenue Next 2Y8.66%
Revenue Next 3Y8.63%
Revenue Next 5Y8.69%
EBIT growth 1Y17.46%
EBIT growth 3Y6.64%
EBIT growth 5Y15.38%
EBIT Next Year31.91%
EBIT Next 3Y16.8%
EBIT Next 5Y14.07%
FCF growth 1Y38.31%
FCF growth 3Y7.86%
FCF growth 5Y21.3%
OCF growth 1Y31.08%
OCF growth 3Y7.13%
OCF growth 5Y15.14%
IDEXX LABORATORIES INC / IDXX FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
Can you provide the valuation status for IDEXX LABORATORIES INC?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
Can you provide the profitability details for IDEXX LABORATORIES INC?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What is the valuation of IDEXX LABORATORIES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 54.71 and the Price/Book (PB) ratio is 35.35.
Can you provide the expected EPS growth for IDXX stock?
The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 14.37% in the next year.